Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) a pragmatic, open-label, non-inferiority, randomised controlled trial
| Autor: | Reinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, Lisa J T Smits, Femke Atsma, Wietske Kievit, Dirk J de Jong, Annemarie C de Vries, Paul J Boekema, Rachel L West, Alexander G L Bodelier, Ingrid A M Gisbertz, Frank H J Wolfhagen, Tessa E H Römkens, Maurice W M D Lutgens, Adriaan A van Bodegraven, Bas Oldenburg, Marieke J Pierik, Maurice G V M Russel, Nanne K de Boer, Rosalie C Mallant-Hent, Pieter C J ter Borg, Andrea E van der Meulen-de Jong, Jeroen M Jansen, Sita V Jansen, Adrianus C I T L Tan, C Janneke van der Woude, Frank Hoentjen, Desirée van Noord, Jildou Hoekstra, Johannes T. Kamphuis, Moniek H.P. Gorter, Aura A.J. van Esch |
|---|---|
| Přispěvatelé: | Gastroenterology and hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology & Hepatology |
| Rok vydání: | 2023 |
| Předmět: |
All institutes and research themes of the Radboud University Medical Center
Hepatology Gastroenterology Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0] Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] Analytical Chemistry Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18] |
| Zdroj: | Lancet Gastroenterology & Hepatology, 8, 4, pp. 343-355 Lancet Gastroenterology & Hepatology, 8, 343-355 The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd LADI study group and the Dutch Initiative on Crohn and Colitis 2023, ' Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) : a pragmatic, open-label, non-inferiority, randomised controlled trial ', The Lancet Gastroenterology and Hepatology, vol. 8, no. 4, pp. 343-355 . https://doi.org/10.1016/S2468-1253(22)00434-4 The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd. |
| ISSN: | 2468-1253 |
| DOI: | 10.1016/S2468-1253(22)00434-4 |
| Popis: | Item does not contain fulltext BACKGROUND: Despite its effectiveness in treating Crohn's disease, adalimumab is associated with an increased risk of infections and high health-care costs. We aimed to assess clinical outcomes of increased adalimumab dose intervals versus conventional dosing in patients with Crohn's disease in stable remission. METHODS: The LADI study was a pragmatic, open-label, multicentre, non-inferiority, parallel, randomised controlled trial, done in six academic hospitals and 14 general hospitals in the Netherlands. Adults (aged ≥18 years) diagnosed with luminal Crohn's disease (with or without concomitant perianal disease) were eligible when in steroid-free clinical and biochemical remission (defined as Harvey-Bradshaw Index [HBI] score |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|